Portal de investigación
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP)
Fecha de publicación:
Fecha Ahead of Print:
Autores organización
Autores
- Ruiz-Patiño A.
- Barrón F.
- Corrales L.
- Mas L.
- Martín C.
- Zatarain-Barrón Z.L.
- Recondo G.
- Ricaurte L.
- Archila P.
- Rodríguez J.
- Sotelo C.
- Viola L.
- Vargas C.
- Carranza H.
- Otero J.
- Pino L.E.
- Rolfo C.
- Rosell R.
- Arrieta O.
Grupos de investigación
Resumen
Background: The intestinal microbiota is an important factor in modulating immune-mediated tumor cell destruction. Alterations in the microbiome composition have been linked to reduced efficacy of immune checkpoint inhibitor (ICI) therapies. Therefore, antibiotic treatment (ATB), which modifies the diversity of the gut bacteria populations, could lead to a reduced efficacy of ICI treatments. Methods: This was a retrospective cohort study. Patients with advanced non-small cell lung cancer (NSCLC) treated with anti-programmed cell death ligand-1 (PD-L1) alone, or in combination in three different countries in Latin America were included. After identification, patients were placed into three groups: Non-ATB exposed (no-ATB), exposed within 30 days of the first dose of ICI (pre-ICI ATB) and patients receiving ATB concomitantly with ICI (ICI-ATB). Progression-free survival (PFS), overall survival (OS) and response rates to treatment with ICI were assessed. Results: A total of 140 patients were included, of which 32 patients (23%) received ATB treatment. The most common ATB types were fluoroquinolones and B-lactams. No differences in survival according to antibiotic type were identified. Median OS in patients not exposed to ATB was 40.6 months (95% CI: 32–67.7), compared with 20.3 months (95% CI: 12.1-non-reached [NR]) for patients with pre-ICI ATB treatment and 24.7 months (95% CI: 13-NR) for patients treated with ATB concomitantly with ICI. There were no significant differences in terms of PFS, or response rates across all treatment groups. Conclusions: Antibiotic treatment was associated with reduced OS in Hispanic patients with NSCLC treated with ICIs. © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 1759-7706, 1759-7714
- Tipo:
- Article
- Páginas:
- 2552-2560
- PubMed:
- 32705787
- Enlace a otro recurso:
- www.scopus.com
Thoracic Cancer John Wiley and Sons Inc
Citas Recibidas en Web of Science: 10
Citas Recibidas en Scopus: 12
Documentos
- No hay documentos
Filiaciones
Keywords
- Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Retrospective Studies; antibiotic agent; antineoplastic metal complex; avelumab; beta lactam antibiotic; ciprofloxacin; clarithromycin; clindamycin; docetaxel; doxycycline; durvalumab; immune checkpoint inhibitor; immunological antineoplastic agent; ipilimumab; meropenem; nitrofurantoin; nivolumab; pembrolizumab; pemetrexed; piperacillin plus tazobactam; platin derivative; programmed death 1 ligand 1; quinoline derived antiinfective agent; unclassified drug; antiinfective agent; adult; advanced cancer; aged; antibiotic therapy; Article; cancer patient; catheter infection; cohort analysis; controlled study; drug antagonism; drug efficacy; drug exposure; female; Hispanic; human; intestine flora; major clinical study; male; multiple cycle treatment; non small cell lung cancer; overall survival; pneumonia; priority journal; progression free survival; ret